AB-MECA is a high-affinity A3 adenosine receptor agonist (activator) with a binding Ki of 430.5 nM for human A3 receptors in CHO cells. AB-MECA increases plasma histamine levels.

Physicochemical Properties

Molecular Formula	C19H23N7O5
Molecular Weight	429.437
Exact Mass	399.166
CAS #	152918-26-8
PubChem CID	5310992
Appearance	Typically exists as solid at room temperature
Density	1.68g/cm3
Index of Refraction	1.789
LogP	0.88
Hydrogen Bond Donor Count	5
Hydrogen Bond Acceptor Count	9
Rotatable Bond Count	5
Heavy Atom Count	29
Complexity	576
Defined Atom Stereocenter Count	4
SMILES	O[C@H]1[C@H](N2C=NC3=C(NCC4=CC=C(N)C=C4)N=CN=C23)O[C@H](C(NC)=O)[C@H]1O
InChi Key	LDYMCRRFCMRFKB-MOROJQBDSA-N
InChi Code	InChI=1S/C18H21N7O4/c1-20-17(28)14-12(26)13(27)18(29-14)25-8-24-11-15(22-7-23-16(11)25)21-6-9-2-4-10(19)5-3-9/h2-5,7-8,12-14,18,26-27H,6,19H2,1H3,(H,20,28)(H,21,22,23)/t12-,13+,14-,18+/m0/s1
Chemical Name	N6-(4-Aminobenzyl)-N-methylcarboxamidoadenosine
Synonyms	AB MECA AB-MECAABMECA
HS Tariff Code	2934.99.9001
Storage	Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Shipping Condition	Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)

Biological Activity

ln Vitro	The human lung cancer cell line A549 demonstrates the expected cytotoxicity when exposed to AB-MECA (1, 10, 100 μM; 24 hours) [2]. In transfected CHO cells and RBL-2H3 cells, the KD values of [125I]AB-MECA binding to A3 uptake were 1.48 and 3.61 nM, respectively [3].
ln Vivo	Histamine levels can be raised intravenously by AB-MECA (3 ug/kg) [4]. Albino guinea pigs (body weight 180–220 g) respond better to medium induction when administered intravenously with AB-MECA (0.3 mg/kg).
Cell Assay	Cytotoxicity assay[2] Cell Types: A549 Cell Tested Concentrations: 1, 10, 100 μM Incubation Duration: 24 hrs (hours) Experimental Results: demonstrated dose-dependent cytotoxicity.
Animal Protocol	Animal/Disease Models: Male balb/c (Bagg ALBino) mouse, weight 18-25 g[4] Doses: 3 ug/kg given Medication: IV; systolic contraction [5]. Single dose Experimental Results: Caused a 5.9-fold increase in histamine levels in mouse plasma.
References	[1]. L Yates, et al. Radioligand binding and functional responses of ligands for human recombinant adenosine A(3) receptors. Auton Autacoid Pharmacol. 2006 Apr;26(2):191-200. [2]. Solanki, N. D., et al. In Vitro Evaluation Of Anti-Cancer Potential Of A3 Adenosine Receptor Agonist On A549 Human Lung Cancer Cell Line. Int J Pharm Pharm Sci ; 2019 Jun; 11(6): 106-108. [3]. X D Ji, et al. A selective agonist affinity label for A3 adenosine receptors. Biochem Biophys Res Commun. 1994 Aug 30;203(1):570-6. [4]. Endre G Mikus, et al. Interaction of SSR161421, a novel specific adenosine A(3) receptor antagonist with adenosine A(3) receptor agonists both in vitro and in vivo. Eur J Pharmacol. 2013 Jan 15;699(1-3):62-6. [5]. Endre G Mikus, et al. Evaluation of SSR161421, a novel orally active adenosine A3 receptor antagonist on pharmacology models. Eur J Pharmacol. 2013 Jan 15;699(1-3):172-9.

Solubility Data

Solubility (In Vitro)

DMSO : ~55 mg/mL (~137.71 mM)

Solubility (In Vivo)

Solubility in Formulation 1: ≥ 2.75 mg/mL (6.89 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 27.5 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.75 mg/mL (6.89 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 27.5 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 3: ≥ 2.75 mg/mL (6.89 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 27.5 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly.  (Please use freshly prepared in vivo formulations for optimal results.)

Preparing Stock Solutions		1 mg	5 mg	10 mg
	1 mM	2.3286 mL	11.6431 mL	23.2861 mL
	5 mM	0.4657 mL	2.3286 mL	4.6572 mL
	10 mM	0.2329 mL	1.1643 mL	2.3286 mL

*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.